参考文献/References:
[1]张婵,孙媛,刘铭,等.HPV病毒感染与宫颈病变发生发展关系的研究进展[J].中国微生态学杂志,2016,28(7):861-864.[2]范成娇,李静,鲁爱枝.HPV52/58感染与女性宫内病变发生风险的相关性研究[J].中国妇幼保健,2015(30):841-843.[3]段超英.宫颈上皮内瘤变患者中人乳头状瘤病毒感染情况分析[J].国际检验医学杂志,2017,38(4):551-552.[4]吴云燕,裘明利.女性高危型人乳头瘤病毒感染分布情况研究[J].中国实用妇科与产科杂志,2017,33(1):122-124.[5]张睿,毕鑫星,叶阿里,等.人乳头瘤病毒在临床患者中的感染现状及主要型别分析[J].中国医学科学院学报,2017,39(4):506-510.[6]陈春宝,苏震,田昕,等.海南2939例女性HPV感染现状及基因型分布[J].中国热带医学,2017,17(9):904-907.[7]刘存芬.安宁市人乳头瘤病毒检测及感染人群特征分析[J].检验医学与临床,2017,14(3):370-372.
相似文献/References:
[1]莫宗平,刘 巧,蒋佳利.安岳地区女性高危型HPV基因分型结果分析[J].医学信息,2018,31(18):101.[doi:10.3969/j.issn.1006-1959.2018.18.031]
MO Zong-ping,LIU Qiao,JIANG Jia-li.Analysis of the Results of High-risk HPV Genotyping in Women in Anyue Area[J].Medical Information,2018,31(16):101.[doi:10.3969/j.issn.1006-1959.2018.18.031]
[2]邬素珍,许焕英.宫颈人乳头瘤病毒感染的免疫研究进展[J].医学信息,2018,31(19):33.[doi:10.3969/j.issn.1006-1959.2018.19.012]
WU Su-zhen,XU Huan-ying.Progress in Immunization of Cervical Human Papillomavirus Infection[J].Medical Information,2018,31(16):33.[doi:10.3969/j.issn.1006-1959.2018.19.012]
[3]许生样.杭州地区男性人乳头瘤病毒感染特征分析[J].医学信息,2020,33(05):137.[doi:10.3969/j.issn.1006-1959.2020.05.043]
XU Sheng-yang.Characteristics of Human Papillomavirus Infection in Male in Hangzhou[J].Medical Information,2020,33(16):137.[doi:10.3969/j.issn.1006-1959.2020.05.043]
[4]秦燕,王杏茶,方淑琴,等.承德市女性人乳头瘤病毒感染基因分型的临床分析[J].医学信息,2020,33(08):144.[doi:10.3969/j.issn.1006-1959.2020.08.047]
QIN Yan,WANG Xing-cha,FANG Shu-qin,et al.Infection Status and Distribution Characteristics of Female HPV Subtypes in Chengde City from 2014 to 2017[J].Medical Information,2020,33(16):144.[doi:10.3969/j.issn.1006-1959.2020.08.047]
[5]张 晴,杨勇莉.p16在宫颈癌发生发展中的作用[J].医学信息,2022,35(01):59.[doi:10.3969/j.issn.1006-1959.2022.01.014]
ZHANG Qing,YANG Yong-li.Role of p16 in the Development of Cervical Cancer[J].Medical Information,2022,35(16):59.[doi:10.3969/j.issn.1006-1959.2022.01.014]
[6]周爱萍.重组人干扰素α-2b注射液联合凝胶对宫颈HPV感染患者炎性因子水平的影响[J].医学信息,2022,35(06):162.[doi:10.3969/j.issn.1006-1959.2022.06.042]
ZHOU Ai-ping.Effect of Recombinant Human Interferon α-2b Injection Combined with Gel on Inflammatory Factor Levels in Patients with Cervical HPV Infection[J].Medical Information,2022,35(16):162.[doi:10.3969/j.issn.1006-1959.2022.06.042]
[7]穆红茹.中晚期宫颈癌的非手术治疗进展[J].医学信息,2022,35(15):167.[doi:10.3969/j.issn.1006-1959.2022.15.040]
MU Hong-ru.Advances in Nonsurgical Treatment of Cervical Cancer in the Middle and Late Stage[J].Medical Information,2022,35(16):167.[doi:10.3969/j.issn.1006-1959.2022.15.040]
[8]翁梦晴,韦彩萍,任文宁,等.基于CiteSpace的人乳头瘤病毒疫苗可视化分析[J].医学信息,2023,36(03):39.[doi:10.3969/j.issn.1006-1959.2023.03.009]
WENG Meng-qing,WEI Cai-ping,REN Wen-ning,et al.Visual Analysis of Human Papillomavirus Vaccine Based on CiteSpace[J].Medical Information,2023,36(16):39.[doi:10.3969/j.issn.1006-1959.2023.03.009]
[9]毛 焕,潘建立,王长友.NLRP3炎症小体基因在HPV感染子宫颈细胞中的表达差异研究[J].医学信息,2023,36(06):114.[doi:10.3969/j.issn.1006-1959.2023.06.025]
MAO Huan,PAN Jian-li,WANG Chang-you.Differential Expression of NLRP3 Inflammasome Gene in HPV-infected Cervical Cells[J].Medical Information,2023,36(16):114.[doi:10.3969/j.issn.1006-1959.2023.06.025]
[10]侯红叶,郭晓青.阴道微生态和细菌性阴道病与宫颈人乳头瘤病毒感染的研究现状[J].医学信息,2024,37(09):184.[doi:10.3969/j.issn.1006-1959.2024.09.038]
HOU Hong-ye,GUO Xiao-qing.Research Status of Vaginal Microecology, Bacterial Vaginosis and Cervical Human Papillomavirus Infection[J].Medical Information,2024,37(16):184.[doi:10.3969/j.issn.1006-1959.2024.09.038]